Brief: Vasomune And Anges Announce Drug Candidate Av-001 Receives Positive Recommendation From The IDSMB
14/11/2023 13:13
Nov 14 (Reuters) - AnGes Inc 4563.T :
* VASOMUNE AND ANGES ANNOUNCE DRUG CANDIDATE AV-001 RECEIVES
POSITIVE RECOMMENDATION FROM THE IDSMB FOR AV001-004 PHASE 2A
STUDY
Source text for Eikon: ID:nBw91cYpKa
Further company coverage: 4563.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001